Jeffrey S. Chamberlain

Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin

J. Chamberlain, M. Reyes, S. Hauschka, 2005, Gene Therapy.

Duchenne muscular dystrophy.

J. Chamberlain, Jeffrey S. Chamberlain, Jacqueline Wicki, 1991, Current opinion in genetics & development.

Immune evasion by muscle-specific gene expression in dystrophic muscle.

J. Mulé, J. Chamberlain, D. Hartigan-O’Connor, 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophy.

S. Tapscott, Sheng Li, Miki Haraguchi, 2008, Human molecular genetics.

Unloaded speed of shortening in voltage-clamped intact skeletal muscle fibers from wt, mdx, and transgenic minidystrophin mice using a novel high-speed acquisition system.

C. Weber, R. Fink, F. von Wegner, 2008, Biophysical journal.

Heparin-binding correlates with increased efficiency of AAV1- and AAV6-mediated transduction of striated muscle, but negatively impacts CNS transduction

R. Palmiter, R. Palmiter, J. Chamberlain, 2012, Gene Therapy.

Characterization of ARC, apoptosis repressor interacting with CARD, in normal and dystrophin-deficient skeletal muscle.

J. Chamberlain, R. Crawford, S. Abmayr, 2003, Human molecular genetics.